[6-K] Radiopharm Theranostics Ltd Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Radiopharm Theranostics Limited furnished a Form 6-K to provide two Australian Securities Exchange announcements. The exhibits include a “Change of Director’s Interest Notice (RC)” and “Presenting at Deutsche Bank ADR Virtual Investor Conference,” both dated November 3, 2025.

The submission states it is not deemed “filed” under the Exchange Act and will not be incorporated by reference into Securities Act filings except by specific reference.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of November 2025

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐       No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published two announcements (the “Public Notice”) to the Australian Securities Exchange on November 3, 2025 titled:

“Change of Director’s Interest Notice (RC)”

“Presenting at Deutsche Bank ADR Virtual Investor Conference”

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

1

EXHIBITS

Exhibit Number		Description
99.1		Change of Director’s Interest Notice (RC)
99.2		Presenting at Deutsche Bank ADR Virtual Investor Conference

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED
Date: November 3, 2025	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

3

FAQ

What did RADX submit in this Form 6-K?

The company furnished two ASX announcements: a “Change of Director’s Interest Notice (RC)” and “Presenting at Deutsche Bank ADR Virtual Investor Conference.”

When were the ASX announcements dated?

Both announcements were dated November 3, 2025.

Are the materials deemed “filed” under the Exchange Act?

No. The submission states it is not deemed “filed” under the Exchange Act.

Will these materials be incorporated by reference into other filings?

They will not be incorporated by reference except where expressly set forth by specific reference.

What are the exhibit numbers in this 6-K for RADX?

Exhibit 99.1 is the Change of Director’s Interest Notice (RC); Exhibit 99.2 is Presenting at Deutsche Bank ADR Virtual Investor Conference.

What type of issuer is Radiopharm Theranostics Limited?

It is a foreign private issuer furnishing information on Form 6-K.